FCF Margin % is calculated as Free Cash Flow divided by its Revenue. GlobeImmune's Free Cash Flow for the
three
months ended in Mar. 2016 was $-1.21 Mil. GlobeImmune's Revenue for the
three
months ended in Mar. 2016 was $0.94 Mil. Therefore, GlobeImmune's FCF Margin % for the quarter that ended in Mar. 2016 was -128.00%.
The historical rank and industry rank for GlobeImmune's FCF Margin % or its related term are showing as below:
GBIM'
s FCF Margin % Range Over the Past 10 Years
Min: -95.22 Med: 0 Max: 0
Current: -95.22
GBIM's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -148.935
vs GBIM: -95.22
GlobeImmune FCF Margin % Historical Data
The historical data trend for GlobeImmune's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of GlobeImmune's FCF Margin %
For the Biotechnology subindustry, GlobeImmune's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GlobeImmune's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, GlobeImmune's FCF Margin % distribution charts can be found below:
* The bar in red indicates where GlobeImmune's FCF Margin % falls into.
GlobeImmune FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
GlobeImmune's FCF Margin for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GlobeImmune FCF Margin % Related Terms
Thank you for viewing the detailed overview of GlobeImmune's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBIM has been successfully added to your 